Scholarlink

<p>Precision oncology has changed first-line therapy in metastatic colorectal cancer (mCRC) considerably. During ASCO 2025, relevant practice-changing data were reported for distinct molecular subgroups. Key trials addressed novel approaches in upfront therapy of BRAF<sup>V600E</sup> mutated (BREAKWATER) and dMMR/MSI‑h mCRC. In comparison with standard of care (SOC), BRAF<sup>V600E</sup> inhibition demonstrated a&#xa0;doubling of overall survival (OS). An update of the CheckMate 8HW trial confirmed the plateauing of OS curves after longer follow-up, suggesting the potential for cure with dual immune blockade in MSI‑h mCRC. Targeting the KRAS<sup>G12C</sup> mutation is also a&#xa0;promising strategy; data were presented for sotorasib plus panitumumab plus FOLFIRI in pretreated patients. Although the numbers are small, the results on objective response rate (ORR), progression-free survival (PFS), and OS are clinically meaningful. Consequently, KRAS<sup>G12C</sup> inhibition is now evaluated in a&#xa0;first-line setting (CodeBreaK 301). Additionally, phase&#xa0;1/2 data for next-generation KRAS<sup>G12C</sup> inhibitors were presented. Immune therapy as part of therapeutic strategies in pMMR/MSS tumors remains a&#xa0;topic of special interest. The results of an interim analysis from early phase&#xa0;1/2 dose finding and dose expansion trials were reported. The aim of this review is to summarize clinically relevant abstracts, focusing on practice-changing trials, and to provide insights into new therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASCO 2025: metastatic colorectal cancer—focus on precision oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Renate Schaberl-Moser

摘要

Precision oncology has changed first-line therapy in metastatic colorectal cancer (mCRC) considerably. During ASCO 2025, relevant practice-changing data were reported for distinct molecular subgroups. Key trials addressed novel approaches in upfront therapy of BRAFV600E mutated (BREAKWATER) and dMMR/MSI‑h mCRC. In comparison with standard of care (SOC), BRAFV600E inhibition demonstrated a doubling of overall survival (OS). An update of the CheckMate 8HW trial confirmed the plateauing of OS curves after longer follow-up, suggesting the potential for cure with dual immune blockade in MSI‑h mCRC. Targeting the KRASG12C mutation is also a promising strategy; data were presented for sotorasib plus panitumumab plus FOLFIRI in pretreated patients. Although the numbers are small, the results on objective response rate (ORR), progression-free survival (PFS), and OS are clinically meaningful. Consequently, KRASG12C inhibition is now evaluated in a first-line setting (CodeBreaK 301). Additionally, phase 1/2 data for next-generation KRASG12C inhibitors were presented. Immune therapy as part of therapeutic strategies in pMMR/MSS tumors remains a topic of special interest. The results of an interim analysis from early phase 1/2 dose finding and dose expansion trials were reported. The aim of this review is to summarize clinically relevant abstracts, focusing on practice-changing trials, and to provide insights into new therapeutic strategies.